small molecule glp-1 agonist Orforglipron, an Oral Small-Molecule Receptor for Obesity November 5, 2025 DOI: 10.1056/NEJMdo008238 New for the treatment of obesity - and so many additional indications being studied Discovery of Small-Molecule GLP-1 Receptor

En cuanto a los efectos secundarios, ha recordado que "los frmacos deben ser prescritos y los tratamientos deben estar controlados por los profesionales sanitarios"

Lang K (2025)

Supplements and Therapies: If needed, consult a healthcare professional to determine the best approach to supplementation, which may include oral supplements or intravenous therapy

renal impairment may require monitoring The one-week half-life of both components enables true once-weekly dosing while maintaining relatively stable plasma concentrations throughout the dosing interval, contributing to consistent therapeutic effects and potentially improved tolerability compared to shorter-acting agents

Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques: a role for apoptosis in plaque thrombogenicity